Health Secretary RFK Jr. says there's 'not sufficient' proof to show Tylenol causes autism

Health Secretary Robert F. Kennedy Jr. stated there is "not sufficient" definitive proof linking Tylenol (acetaminophen) to autism, though he still advises caution during pregnancy due to "suggestive" evidence, softening previous, more absolute warnings from himself and former President Donald Trump. This comes as the FDA announced it would initiate a safety label change process for acetaminophen due to a "potential association" with neurodevelopmental outcomes, while also noting conflicting studies and risks of untreated fever. Concurrently, Texas has sued Tylenol maker Kenvue, which maintains there is no scientific link to autism and defends its product, while its shares experienced a 1.4% decline on the news, reflecting ongoing regulatory, legal, and market uncertainty for the widely used painkiller.

Analysis

Health Secretary RFK Jr. stated there is "not sufficient" definitive proof linking Tylenol to autism, yet advised caution during pregnancy due to "suggestive" evidence, marking a shift from prior absolute warnings. Concurrently, the FDA announced it would initiate a safety label change process for acetaminophen, citing a "potential association" with neurodevelopmental outcomes, while acknowledging conflicting studies and risks of untreated fever. This indicates a complex regulatory environment balancing potential risks with established medical benefits.

The state of Texas has sued Kenvue, the maker of Tylenol, alleging the company concealed data regarding health risks. Kenvue has consistently defended its product, asserting no scientific link between acetaminophen and autism, and has urged the FDA to reject an autism warning label. The company's stance emphasizes the importance of consulting healthcare professionals, aligning with RFK Jr.'s latest advice.

Kenvue shares reacted negatively, declining 1.4% at market close on October 29, reflecting investor concern over the ongoing legal and regulatory scrutiny. The per-ticker sentiment for KVUE is significantly negative (-0.75), indicating market apprehension despite the Health Secretary's more tempered statement. This situation introduces considerable uncertainty for Kenvue's core product line and future revenue streams.

Key Decisions for Investors

• Monitor Kenvue's legal proceedings in Texas and the FDA's progress on potential acetaminophen label changes, as these events could significantly impact future sales and brand perception.
• Evaluate Kenvue's risk-adjusted valuation given the ongoing regulatory and litigation pressures, which introduce uncertainty to its core product's market position.
• Assess the broader implications for other consumer health companies with widely used over-the-counter medications, as increased scrutiny on long-standing products could set new precedents.